A new case study published in Cureus by Saami Khalifian, MD; Alec D. McCarthy, MD; and Steven Yoelin, MD, examines the efficacy and safety of an injectable therapy for treating neck wrinkles and skin laxity. This therapy combines hyperdiluted calcium hydroxylapatite (CaHA), platelet-rich plasma (PRP), and hyaluronidase.
Two patients with moderate neck wrinkles and skin laxity received the treatment and were evaluated several months later.
The study found that a single treatment with the combined therapy improved skin texture and laxity.
The inclusion of PRP and hyaluronidase aimed to enhance the regenerative effects of CaHA. PRP is rich in growth factors that stimulate collagen production and regeneration, while hyaluronidase breaks down hyaluronic acid, promoting better diffusion and even product dispersion.
The findings from these cases provide preliminary evidence supporting the safety and efficacy of this innovative combination therapy for addressing neck wrinkles and laxity.
According to the researchers, this is the first documented instance of using CaHA in conjunction with hyaluronidase and PRP for skin priming.
Further investigations are needed to explore the application of this treatment for other anatomical regions and to clarify the role of each injected component.
Read complete findings at Cureus
More from The Blog
JEM MedSpa Adds EXOMIND for Depression: Wellness in Aesthetics Grows
The world of aesthetic medicine is evolving. Today’s top medspas aren’t just helping clients look better—they’re helping them feel better, too. A powerful example of this shift is JEM MedSpa in Orland Park, Illinois. Known for their cutting-edge aesthetic treatments,...
Medspa Branding Warning: What the Renu vs. Renew Domain Case Teaches About Domain Name Disputes
If you're building your medspa brand online, choosing the right name—and securing your domain—is critical. But a recent UDRP case involving two Idaho-based spas shows what can happen when businesses try to strong-arm their way into domain ownership. In short? One spa...
FDA Cracks Down: Compounding Pharmacies Ordered to Stop Copying Ozempic and Wegovy
In a move that's sending ripples through the healthcare, telehealth, and weight-loss industries, a U.S. judge has rejected an attempt by compounding pharmacies to keep producing copies of Novo Nordisk’s blockbuster drugs, Ozempic and Wegovy. This decision ensures that...
AbbVie Files Fast-Acting/Shorter-Duration Botox Alternative for FDA Approval
In major news for the medspa industry, AbbVie has filed for approval of a fast-acting, short-duration Botox alternative known as TrenibotulinumtoxinE (TrenibotE). This new injectable aims to target moderate to severe frown lines with results that start showing in as...
